Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma by Zheng, Min et al.
Inhibition of the prolyl isomerase Pin1
enhances the ability of sorafenib to
induce cell death and inhibit tumor
growth in hepatocellular carcinoma
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Zheng, M., H. Xu, X. Liao, C. Peng Chen, A. Li Zhang, W. Lu, L. Wang,
et al. 2017. “Inhibition of the prolyl isomerase Pin1 enhances the
ability of sorafenib to induce cell death and inhibit tumor growth
in hepatocellular carcinoma.” Oncotarget 8 (18): 29771-29784.
doi:10.18632/oncotarget.15967. http://dx.doi.org/10.18632/
oncotarget.15967.
Published Version doi:10.18632/oncotarget.15967
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33439348
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget29771www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 18), pp: 29771-29784
Inhibition of the prolyl isomerase Pin1 enhances the ability 
of sorafenib to induce cell death and inhibit tumor growth in 
hepatocellular carcinoma
Min Zheng1,2,*, Huijuan Xu1,2,*, Xin-Hua Liao1,2,*, Champ Peng Chen1,2, Arina Li 
Zhang1,2, Wenxian Lu1,2, Long Wang1,2, Dayun Yang1,2, Jichuang Wang1,2, Hekun 
Liu1,2, Xiao Zhen Zhou1,2,3, Kun Ping Lu1,2,3
1Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational 
Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China
2Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian 350108, China
3Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
*These authors contributed equally to this work
Correspondence to: Kun Ping Lu, email: klu@bidmc.harvard.edu
Keywords: sorafenib, Pin1, ATRA, HCC, cell death
Received: September 27, 2016    Accepted: January 24, 2017    Published: March 07, 2017
Copyright: Zheng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Hepatocellular carcinoma (HCC) is the sixth most common cancer, but is the second 
leading cause of cancer deaths, partially due to its heterogeneity and drug resistance. 
Sorafenib is the only medical treatment with a proven efficacy against advanced 
HCC, but its overall clinical efficacy is still modest. Therefore, a major challenge is 
how to improve its therapeutic efficacy. The unique prolyl isomerase Pin1 regulates 
numerous cancer-driving pathways. Notably, Pin1 is overexpressed in about 70% HBV-
positive HCC patients and contributes to HCC tumorigenesis. However, the role of Pin1 
in the efficacy of sorafenib against HCC is unknown. Here we found that sorafenib 
down-regulated Pin1 mRNA and protein expression, likely through inhibition of Pin1 
transcription by the Rb/E2F pathway. Importantly, Pin1 knockdown potently enhanced 
the ability of sorafenib to induce cell death in HCC, which was further supported by the 
findings that Pin1 knockdown led to stabilization of Fbxw7 and destabilization of Mcl-1. 
Furthermore, all-trans retinoic acid (ATRA), a known anticancer drug that inhibits and 
ultimately induces degradation of active Pin1 in cancer cells, also potently sensitized 
HCC cells to sorafenib-induced cell death at least in part through a caspase-dependent 
manner. Moreover, ATRA also synergistically enhanced the ability of sorafenib to reduce 
Pin1 and inhibit tumor growth of HCC in mouse xenograft models. Collectively, these 
results not only demonstrate that Pin1 down-regulation is a key event underlying the 
anti-tumor effects of sorafenib, but also uncover that Pin1 inhibitors offer a novel 
approach to enhance the therapeutic efficacy of sorafenib against HCC.
INTRODUCTION
Liver cancer is the sixth most common cancer 
worldwide, with 782000 new cases diagnosed in 2012 [1]. 
In contrast to stable or declining trends of most cancers, 
the incidence rate of liver cancer increases from 2003 to 
2012 in the United States [2]. More importantly, liver 
cancer has moved up to the second leading cause of 
cancer-related deaths in the world. This is partially due to 
lack of efficacious targeted therapy to control high inter- 
and intra-tumor heterogeneity and complexity of etiology 
in this cancer, with multiple cancer-driving pathways 
being often activated at the same time.
Sorafenib is the only medical treatment that was 
approved by the US Food and Drug Administration for the 
treatment of advanced hepatocellular carcinoma (HCC) with 
a proven efficacy [3–7]. Sorafenib was originally designed 
to target on the Raf family of protein kinases, which control 
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cell proliferation and tumor development in many types of 
cancer including HCC [8]. Pharmacological profiling studies 
have identified several receptor tyrosine kinases as its targets, 
such as VEGFR1/2/3/, PDGFR, c-Kit and RET, conferring 
sorafenib as a multi-kinase inhibitor [9]. However, patients 
with advanced HCC only benefit no more than 3 months 
survival advantage from sorafenib treatment [4]. 
As a consequence of the lack of more effective 
compounds or treatment strategies, a major aim of biological 
research is to improve the efficacy of sorafenib against 
HCC [7]. VEGFA amplification was identified as a key 
biomarker for patients who might be sensitive to sorafenib 
treatment [10]. In another study, in vivo RNA interference 
screening targeting on genes located within focal genomic 
amplification identified MAPK14 as a key regulator of 
sorafenib resistance in liver cancer [11]. Combinational 
blockade of MAPK14 and other key regulators is proposed 
to overcome sorafenib resistance in human HCC[12]. 
These two pioneer works implicate a promise for sorafenib 
precision therapy and combinational therapy in HCC. 
Recently, to enhance the ability of sorafenib to induce 
cell death in HCC has been proposed to be a new strategy. 
Sorafenib alone leads to apoptosis [13] or iron dependent 
cell death, named ferroptosis [14], in a cell type specific 
manner. The role of sorafenib in HCC cell death is attributed 
to down-regulating Bcl-2 family member, Mcl-1 (Myeloid 
Cell Leukemia-1) [15]. Sorafenib blocks Erk mediated 
Mcl-1 phosphorylation on Thr92, which de-stabilizes Mcl-
1 [16]. On the other hand, sorafenib activates GSK3beta 
by attenuating the inhibitory phosphorylation on Ser9 [17]. 
Activated GSK3beta phosphorylates Mcl-1 on Ser159 
and Thr163, leading to its interaction with Fbxw7, an E3 
ubiquitin ligase [18]. Additional mechanisms have been 
reported in other cancer types. Sorafenib has been shown 
to perturb mitochondrial function and reduce intracellular 
ATP levels, leading to activation of AMP-activated protein 
kinase (AMPK) and inhibition of mTORC1 activity, which 
finally promotes cell death in breast cancer cells [19]. 
Sorafenib can also induce down-regulation of survivin, 
leading to apoptotic cell death in human non-small lung 
cancer cells [20]. However, Sorafenib does not target these 
proteins directly so that the upstream regulators for this 
process remain to be elucidated.
The unique prolyl isomerase, Pin1 is prevalently 
overexpressed or over-activated in many types of cancer 
including HCC [21, 22]. Accumulating evidences 
have demonstrated that Pin1 plays a key role in cancer 
development, progression and prognosis by turning on more 
than 40 oncogenes/growth-promoting proteins and turning 
off more than 20 tumor suppressors/growth-inhibiting 
proteins at the same time [21]. Pin1 catalyzes cis-trans 
isomerization of specific phosphorylated Ser/Thr-Pro motifs 
and induce conformational change of proteins after proline-
directed Ser/Thr phosphorylation [23], thereby affecting 
activities and stabilities of its substrates [24]. Notably, 
Pin1 is specifically overexpressed in more than 70% HBV-
related HCC in China [22, 25] and Pin1 overexpression 
transforms normal liver cells [26]. Interestingly, many 
mediators of sorafenib induced cell death, such as Fbxw7, 
Mcl-1, survivin and AMPK are phosphorylated on Ser/
Thr-Pro motif and their protein stabilities and activities 
are regulated by Pin1-catalyzed cis-trans isomerization 
[16, 24, 27–29]. However, the role of Pin1 in the HCC 
treatment, especially sorafenib-based targeted therapy is 
still uncharacterized. Given the critic role of Pin1 in HCC 
development [30], we investigate whether Pin1 plays a role 
in anti-tumor effects of sorafenib in HCC. In this present 
study, we showed that Pin1 expression is down regulated 
upon sorafenib treatment and inhibition of Pin1 either by 
genetic or chemical ablation potentiates anti-tumor efficacy 
of sorafenib against HCC in vitro and in vivo.
RESULTS
Sorafenib down-regulates Pin1 expression in 
multiple human HCC cells
To determine the role of Pin1 in response of 
HCC cells to Sorafenib, we first examined the effect of 
sorafenib on Pin1 expression. Human HCC cell lines, 
Huh7 and HepG2 cells, were treated with sorafenib 
for indicated times. Sorafenib dramatically suppressed 
Pin1 biosynthesis and accumulation both in Huh7 and 
HepG2 cells (Figure 1A and 1B). Dose-response analysis 
for sorafenib induced Pin1 down-regulation was also 
performed in Huh7, HepG2 and PLC/PRF/5 cells. 
Sorafenib treatment led to a does-dependent decrease 
in Pin1 protein levels, as compared to vehicle controls 
in all HCC cell lines examined (Figure 1C, 1E and 1G). 
To further investigate whether sorafenib down-regulated 
Pin1 expression at the mRNA level, real-time PCR was 
performed to detect Pin1 mRNA levels in Huh7, HepG2 
and PLC/PRF/5 treated with 5 µM sorafenib for 24 
hours. Sorafenib treatments also significantly down-
regulated Pin1 mRNA (Figure 1D, 1F and 1H). The 
ability of sorafenib to reduce Pin1 expression was further 
confirmed by the observations that sorafenib attenuated 
Rb phosphorylation on Serine 807/811 (Figure 1I) in 
a dose-dependent manner, which was correlated with 
down-regulation of Pin1 protein (Figure 1I). These 
results are consistent with the previous findings that the 
Rb-E2F pathway regulates Pin1 transcription [31] and 
that sorafenib inhibits the Rb-E2F pathway by reducing 
Rb phosphorylation on Serine 807/811 [32]. These data 
together show that sorafenib down-regulates Pin1 mRNA 
and protein expression in multiple human HCC cells. 
Pin1 knockdown potently enhances the ability of 
sorafenib to induce cell death 
Inducing direct cytotoxicity in cancer cells is one 
of the main goals of anticancer treatments [33]. Although 
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Figure 1: Sorafenib down-regulates Pin1 mRNA and protein expression. (A, B) Sorafenib inhibited Pin1 biosynthesis and 
accumulation in Huh7 and HepG2 cells. Cells were treated with 5 or 10 µM sorafenib for indicated times. Pin1 protein expression was 
determined by Western Blot. (C, E, G) Sorafenib down-regulated Pin1 protein expression in multiple HCC cell lines. Huh7, HepG2 and 
PLC/PRF/5 cells were treated with different doses of sorafenib. Pin1 protein expression was determined by Western Blot. Expression of each 
protein was quantified using Image pro plus 6. (D, F, H) Sorafenib down-regulated Pin1 mRNA expression. Huh7, HepG2 and PLC/PRF/5 
cells were treated with 5 µM sorafenib. Pin1 mRNA expression was determined by real-time PCR. (I) Down-regulation of RB phosphorylation 
on Ser807/Ser811 was associated with Pin1 protein expression in response to sorafenib treatment. Huh7 cells were treated with different doses 
of sorafenib for 24 hours. Phosphorylation of RB on Ser807/Ser811 and Pin1 expression were determined by Western Blot.
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Sorafenib has been shown to induce cell death in HCC 
cells, it is weakly pro-apoptotic as a single agent [13]. In 
order to investigate the significance of Pin1 in sorafenib-
induced cell death, we stably knocked down Pin1 
expression in Huh7, HepG2 and SK-Hep-1 HCC cells 
using validated Pin1 shRNA lentiviruses, which led to 
effective Pin1 knockdown, as compared with scrambled 
shRNA control cells (Figure 2A, 2D and 2G), as described 
previously [34]. Pin1 knockdown and control cells were 
treated with 10 µM sorafenib for 72 hours and stained 
with propidium iodide (pI) and Hoechst33342, which 
have been previously shown to stain dead/late apoptotic 
and early apoptotic/normal cells, respectively [35, 36]. 
Silencing Pin1 expression by genetic knockdown 
drastically enhanced the ability of sorafenib to induce cell 
death in these HCC cell lines, as indicated by pI staining 
(Figure 2B, 2E and 2H). Moreover, the effects were also 
dependent on the dose of sorafenib (Figure 2C, 2F and 2I). 
These results demonstrate that Pin1 knockdown potently 
enhances the ability of sorafenib to induce cell death in 
multiple human HCC cells. 
Next, we investigated the molecular mechanisms 
underlying the effects of Pin1 in sorafenib-induced 
cell death. Pin1 has been shown to regulate multiple 
anti- or pro-apoptotic proteins, such as Bax [37], Mcl-1 
[16] and survivin [28]. Sorafenib has also been shown 
to induce cell death through activation of Bax [38] or 
down-regulation of Mcl-1 [39] and survivin [20]. The 
degradation of Mcl-1 has been shown to depend on Erk-
mediated phosphorylation [16] and Fbxw7-mediated 
ubiquitin-proteasome pathway [18]. Interestingly, it has 
been shown that Pin1 stabilizes Mcl-1 through direct 
binding to Mcl-1 [16] and promoting Fbxw7 degradation 
[40]. Therefore, we examined the expression of these 
Pin1 substrate proteins in Pin1 knockdown and control 
cells. Pin1 knockdown led to up-regulation of Fbxw7 in 
Huh7, HepG2, Hep3B and PLC/PRF/5 cells (Figure 3A 
and 3B), as expected from the previous studies [40]. Bax 
activation was detected in Pin1 knockdown Huh7 and 
Hep3B cells (Figure 3A), while Mcl-1 down-regulation 
was detected in Pin1 knockdown PLC/PRF/5 and HepG2 
cells (Figure 3B). Furthermore, sorafenib induced Mcl-1 
degradation was dose-dependent and correlated with Pin1 
down-regulation (Figure 3C). These data implicate that 
Pin1 shRNA potently enhances the ability of sorafenib to 
induce cell death in HCC cells, which is further supported 
by the findings that Pin1 knockdown leads to the 
stabilization of Fbxw7 and the destabilization of Mcl-1. 
The Pin1 chemical inhibitor ATRA sensitizes 
HCC cells to sorafenib-induced cell death 
Since shRNA could have off-target effects and it 
is still very challenging to deliver shRNA to tumors for 
cancer therapy, we used a small molecular Pin1 inhibitor, 
ATRA, which has been identified through a mechanism-
based screening from a compound library [41]. ATRA 
binds to active Pin1 selectively in cancer cells, leading 
to its degradation and exerting potent anti-tumor activity 
against acute promyelocytic leukemia and breast cancer 
[41]. Although 25 µM ATRA had moderate effects on 
Pin1 expression probably due to cytochrome P450-
dependent ATRA metabolism in HCC cells, as we have 
shown [42, 43], ATRA significantly enhanced sorafenib-
induced down-regulation of Pin1 expression (Figure 4A 
and 4B), demonstrating a synergistic effect of ATRA 
and sorafenib on reducing Pin1 expression. Accordingly, 
sorafenib and ATRA also had synergistic effects on Pin1 
downstream targets, including expression of Fbxw7, Mcl-1 
and survivin, and phosphorylation of AMPK on Thr172 
(Figure 4A and 4B).
In order to investigate whether ATRA also enhances 
sorafenib-induced cell death, we treated HepG2 cells with 
increasing doses of sorafenib in the absence or presence 
of ATRA for 72 hours, followed by assaying dead and live 
cells using flow cytometry after pI staining, as described 
[44]. ATRA alone could not induce cell death, as shown 
previously [41] and sorafenib weakly induced cell death 
(Figure 4C), as shown before [13]. However, a combination 
of ATRA with sorafenib led to a significant increase in cell 
death (Figure 4C and 4D), supported by the synergistic 
reduction of the intracellular ATP level (Figure 4E). 
ATRA also dramatically enhanced sorafenib-induced 
inhibition of cell growth (Supplementary Figure 1A) and 
colony formation (Supplementary Figure 1B and 1C) in 
Huh7 cells. Furthermore, these results indicate that ATRA 
enhances the ability of sorafenib to reduce Pin1 expression 
and to induce cell death. 
Since ATRA directly binds to Pin1, leading to 
inhibition of its enzyme activity and eventual its protein 
degradation [45], we proposed that the molecular 
mechanism underlying the synergistic Pin1 down-
regulation induced by sorafenib and ATRA could be 
due to a combinational effect of sorafenib-mediated 
Pin1 biosynthesis inhibition and ATRA-mediated Pin1 
degradation. Indeed, the proteasome inhibitor MG132 
could partially reversed the synergistic effect, but not 
sorafenib-induced Pin1 down-regulation (Figure 5A). 
To investigate the role of Pin1 down-regulation in the 
combination of sorafenib- and ATRA-induced cell 
death, we compared the effects of sorafenib and ATRA 
in Pin1 knockdown and control cells. In both Huh7 
and HepG2 cells, Pin1 knockdown attenuated ATRA-
mediated enhancement of sorafenib-induced cell death 
(Figure 5B and 5C). Accordingly, Pin1 knockdown 
enhanced sorafenib-induced activation of AMPK and 
attenuated ATRA-mediated enhancement of sorafenib-
induced activation of AMPK (Figure 5D).
In order to determine the molecular mechanisms 
underlying cell death induced by the combination of 
sorafenib and ATRA, we treated Huh7 cells with several 
potent cell death inhibitors. Interestingly, zVAD, a caspase 
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inhibitor, dramatically blocked cell death induced by the 
combination of sorafenib and ATRA (Figure 6A and 6B). 
In contrast, necrostatin-1 (Nec-1, a necroptosis inhibitor), 
ferrostatin-1 (Fer-1, a ferroptosis inhibitor), deferoxamine 
(DFX, an iron chelator) or chloroquine (CQ, an autophagy 
inhibitor) had little influence on sorafenib induced 
cell death (Figure 6A and 6B). Moreover, the effect of 
zVAD on cell death induced by sorafenib and ATRA was 
dose-dependent (Figure 6C). Supportively, synergistic 
activation of caspase 9 and caspase 3 were also observed 
under sorafenib and ATRA combinational treatment 
(Figure 6D). Together, these data indicates that ATRA 
enhances the ability of sorafenib to induce apoptosis in 
HCC cells.
The Pin1 chemical inhibitor ATRA 
synergistically enhances the ability of sorafenib 
to inhibit tumor growth of HCC in vivo 
Given the potent ability of the Pin1 chemical 
inhibitor ATRA to enhance sorafenib-induced cell death 
in HCC cell lines, a critical question is whether ATRA 
would affect the anti-tumor efficacy of sorafenib in HCC 
in vivo. To address this question, Huh7 cells were injected 
subcutaneously into nude mice to establish xenograft 
tumor and 16 days later, when the tumors were detectable, 
mice were randomly grouped into four groups and treated 
with sorafenib, ATRA or combination of sorafenib and 
ATRA or vehicle saline, respectively. ATRA was implanted 
Figure 2: Knockdown of Pin1 sensitizes HCC cells to sorafenib-induced cell death. (A, D, G) Pin1 was knocked down in 
multiple HCC cell lines. Huh7, HepG2 and SK-Hep-1 cells were knocked down using shRNA. Protein expression of Pin1 and beta-actin or 
GAPDH was determined by Western Blot. (B, E, H) Pin1 knockdown enhanced sorafenib induced cell death. Huh7, HepG2 and SK-Hep-1 
cells were treated with 10 µM sorafenib. Cells were stained with pI and Hoechst 33342, photographed under microscopy. (Red: pI positive. 
Blue: Hoechst positive). (C, F, I) Pin1 enhanced cell death induced by sorafenib was dose dependent. Huh7, HepG2 and SK-Hep-1 cells 
were treated with different doses of sorafenib. Cells were stained with pI and Hoechst 33342. The number of red and blue spots were counted 
using Image pro plus 6. Sorafenib induced Cell death in Huh7, HepG2 and SK-Hep-1 cells were determined by the ratio of Red/Blue.
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under the skin in the back of the neck using a slow 
releasing formula, as described [41]. Sorafenib was given 
by oral gavage, as described [10]. A low dose of ATRA 
(one-fourth pellet of 10 mg over 21 days) alone had the 
modest effect on tumor growth, while sorafenib alone did 
not inhibit tumor growth until the late stages (Figure 7A). 
By contrast, the combination of ATRA with sorafenib 
completely stopped HCC tumor growth, even leading to 
tumor shrinkage at the late stage (Figure 7A). When the 
tumors were harvested, weights of tumors treated with 
the combination of ATRA and sorafenib were only one-
third of those treated with vehicle or ATRA alone, and 
one half of those treated with sorafenib alone (Figure 7B 
and 7C), demonstrating the strong synergistic effect of 
ATRA with sorafenib in inhibiting tumor growth in vivo. 
These results were further confirmed by the findings that 
Pin1, and its substrate effectors Mcl-1 and survivin, were 
down-regulated by sorafenib, and largely depleted by a 
combination of sorafenib and ATRA in tumors (Figure 7D). 
Consistent with the findings that a synergistic effect of 
sorafenib and ATRA on cell death could be blocked by the 
caspase inhibitor zVAD, cleavage of caspase 9 and caspase 
3 were robustly detected upon combinational treatment of 
sorafenib and ATRA, indicating that sorafenib and ATRA 
synergistically inhibit tumor growth by inducing apoptosis. 
Taken together, these data consistently demonstrate that 
ATRA synergistically enhances the ability of sorafenib to 
induce Pin1 down-regulation, cell death and inhibit tumor 
growth of HCC in vivo.
DISCUSSION
Sorafenib is the only medical treatment for the 
treatment of advanced HCC with a proven efficacy, but its 
effect is still limited [3–7]. Therefore, the identification of 
key factors and developing combinational drugs to enhance 
the efficacy of sorafenib in HCC is one of the attractive 
strategies. Here we show that sorafenib down-regulated 
Pin1 protein by inhibiting its biosynthesis. Genetic 
knockdown of Pin1 sensitized HCC cells to sorafenib-
induced cell death. Moreover, the Pin1 chemical inhibitor 
ATRA not only enhanced the ability of sorafenib to 
induce cell death of multiple human HCC cells in vitro, 
but also synergistically potentiated sorafenib to suppress 
human HCC tumor growth in mice. These results 
demonstrate for the first time that Pin1 down-regulation 
is one of the key events underlying the anti-tumor 
effects of sorafenib and more importantly, uncover that 
Pin1 inhibitors offer a novel approach to enhance the 
therapeutic efficacy of sorafenib against HCC.
Sorafenib was originally designed to target on Raf 
family, which is a Ser/Thr kinase and a pivotal regulator 
Figure 3: Pin1 affects sorafenib-induced cell death through regulation of Mcl-1 and Bax protein expression. (A) Fbxw7 
and Bax were up-regulated in Pin1 knockdown Huh7 and Hep3B cells. Pin1 was knocked down in Huh7 and Hep3B cells. Protein expression 
of Pin1, Fbxw7, Bax and beta-tubulin was determined by Western Blot. (B) Fbxw7 was up-regulated and Mcl-1 was down-regulated in Pin1 
knockdown PLC/PRF/5 and HepG2 cells. Pin1 was knocked down in PLC/PRF/5 and HepG2 cells. Protein expression of Pin1, Fbxw7, 
Mcl-1 and beta-tubulin was determined by Western Blot. (C) Down-regulation of Mcl-1 is associated with Pin1 expression upon sorafenib 
treatment. Pin1 knocked down HepG2 and its counterpart cells were treated with different doses of sorafenib for 24 hours. Expression of 
Pin1, Mcl-1 and beta-actin was determined by Western Blot.
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of cellular proliferation [46]. Recently, an increasing 
body of evidence has shown that sorafenib has a profound 
impact on cellular signaling [9]. For example, Sorafenib 
turns off transcriptional and translational machinery by 
activating Rb and suppressing mTORC1, respectively 
[32]. In this study, we show for the first time sorafenib 
could down-regulate Pin1 expression at least in part 
through inhibiting its mRNA transcription by the E2F/
Rb pathway. Given the fact that Pin1 promotes cancer 
development through activating more than 40 oncogenes/
growth-promoting proteins and inactivating over 20 
tumor suppressors [21], sorafenib induced Pin1 down-
regulation might in part account for its multiple targeting 
effect in HCC.
Figure 4: The Pin1 inhibitor ATRA sensitizes HCC cells to sorafenib-induced cell death. (A, B) ATRA synergistically 
enhanced sorafenib-induced down-regulation of Pin1 in HCC cell lines. HepG2 and Huh7 cells were treated with 5 µM sorafenib, 25 µM 
ATRA or their combination for 24 hours; Pin1, Fbxw7, Mcl-1, survivin and tubulin protein expression and phosphorylation of AMPK on 
Thr172 were determined by Western Blot. (C, D, E) ATRA synergistically enhanced sorafenib induced cell death. Huh7 cells were treated 
with 5 µM sorafenib, 25 µM ATRA or their combination for 72 hours; cell death was stained by pI and analyzed with flow cytometry (C). 
Alternatively, cells were stained with pI and Hoechst 33342. The number of red and blue spots were counted using Image pro plus 6. 
Sorafenib induced cell death were determined by the ratio of Red/Blue (D). Huh7 cells were treated with 5 µM sorafenib, 25 µM ATRA or 
their combination for 36 hours. Intercellular ATP level was determined (E).
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Figure 5: Sorafenib and ATRA synergistically induce cell death through down-regulating Pin1. (A) Cells were treated as 
indicated (sorafenib, 10 µM; ATRA, 25 µM; MG132, 10 µM) for 12 hours. Pin1 expression was determined by Western Blot. (B, C) HepG2 
and Huh7 cells were treated as indicated (Sorafenib, 5 µM; ATRA, 25 µM) for 72 hours, stained with pI and Hoechst 33342, photographed 
and counted using Image pro plus 6. (D) Pin1 and survivin protein expression, and phosphorylation of AMPK on Thr172 and Erk1/2 on 
Thr202/Y204 were determined by Western Blot. 
Figure 6: Cell death induced by the combination of sorafenib and ATRA is blocked by the caspase inhibitor zVAD in 
Huh7 cells. (A, B) Cell death induced by sorafenib and ATRA was blocked by zVAD in Huh7 cells. Huh7 cells were treated as indicated 
(Sorafenib, 5 µM; ATRA, 25 µM; zVAD, 20 µM; Nec-1, 40 µM; Fer-1, 20 µM; DFX, 200 µM; CQ, 50 µM). Cell death was stained with pI and 
analyzed by FACs (A). Huh7 cells were treated as indicated, stained with pI and Hoechst 33342, photographed and counted using Image pro 
plus 6.0 (B). (C) zVAD blocked cell death induced by sorafenib and ATRA in a dose dependent manner. Huh7 cells were treated with different 
doses of zVAD, stained with pI and Hoechst 33342, photographed and counted using Image pro plus 6. (D) Huh7 cells were treated with 
25 µM ATRA or 5 µM sorafenib or their combination for 48 hours. The protein levels of cleaved caspase 9 and caspase 3 were determined.
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It has become evident that blocking a single pathway 
may not be effective in solid tumors, especially aggressive 
or drug-resistant ones due to feedback and simultaneous 
activation of a wide range of interactive and/or redundant 
pathways [21, 47, 48]. Especially, liver cancer is a highly 
inter- and intra-tumor heterogeneous disease [49] so 
that targeting multiple cancer-driving pathways has its 
advantage in cancer therapy. Notably, Pin1 promotes 
cancer development by turning on and off dozens of 
oncogenes and tumor suppressors, respectively [21]. 
Moreover, Pin1 knockout mice develop normally [50] but 
are highly resistance to Ras, Neu/HER2 induced breast 
cancer [51] or Myc-induced Burkitt’s lymphoma [52]. 
These results indicate that Pin1 is dispensable in normal 
cells but is required for tumor cells, which confers Pin1 
as an ideal anti-tumor candidate. These results implicate 
a promise for Pin1-targeting therapy in HCC, especially 
given its overexpression in about 70% HBV-related HCC 
[22]. However, to test this possibility was challenging due 
to lack of functional active Pin1 inhibitors until the recent 
identification of ATRA as a Pin1 inhibitor [21, 41]. 
The ability of ATRA to enhance sorafenib-induced 
cell death has been shown in acute myeloid leukemia [53] 
and liver cancer [54, 55], but the underlying molecular 
mechanisms are still largely unknown. In this study, we 
show that sorafenib and ATRA have strong synergic 
effect on Pin1 down-regulation both in vitro and in vivo, 
indicating a pivotal role of Pin1 on sorafenib induced cell 
death. Indeed, both genetic knockdown and chemical 
inhibition using ATRA could dramatically increase 
sorafenib induced cell death. This is of particular interest 
since enhancing sorafenib-induced cell death in HCC is 
expected to improve clinical benefit from sorafenib. Our 
xenograft mice data have shown that sorafenib alone 
leads to tumor stasis only later stages, but not shrinkage 
of tumor size, as shown previously [56], which could be 
attributed to its inhibitory effect on cell growth, but not 
cell survival. By contrast, the combination of sorafenib 
Figure 7: The Pin1 inhibitor ATRA synergistically enhances the ability of sorafenib to inhibit tumor growth of HCC 
in vivo. (A) Tumor growth was significantly inhibited by the combination of sorafenib and ATRA. Huh7 cells were injected subcutaneously 
into nude mice. Drugs were administrated when tumors at the point indicated by the arrow. 1/4 tablet of 10 mg 21 day slow-releasing ATRA 
pellet was inoculated subcutaneously. Sorafenib (40 mg/kg) was orally given every three days. Tumor growth was measured every 3 days, 
and tumor volume was calculated using the formula of length*width*width/2. (B, C) ATRA synergistically enhanced sorafenib anti-tumor 
effect in vivo. Tumors were harvested (B) and weighted (C) when the length of largest tumor reached 1.0 cm. (D) ATRA synergistically 
enhanced sorafenib induced Pin1 down-regulation in vivo. Pin1, Mcl-1, survivin, beta-actin, beta-tubulin, cleaved caspase 9 and caspase 3, 
protein expressions were determined by Western Blot.
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with slow-releasing ATRA not only potently stops 
HCC tumor growth, but also leads to decline of tumor 
volumes. These results suggest that clinical combination 
of sorafenib and the Pin1 inhibitor ATRA might be a new 
strategy to improve therapeutic efficacy in HCC. However, 
ATRA has a short half-life of 45 min in humans [57] and 
regular ATRA has moderate but detectable efficacy against 
solid tumors in some clinical trials, new generations of 
supposedly much more potent retinoid derivatives to 
target RARs or RXRs show little efficacy [58–62], which 
is likely due to the failure of these retinoids to inhibit Pin1 
[41]. Taken together, these results provide a rationale for 
developing longer half-life ATRA or more potent and 
specific Pin1-targeted ATRA variants to overcome drug 
resistance in cancer therapy, especially in combination 
with sorafenib for HCC. 
In summary, our results have identified Pin1 
down-regulation as a key event underlying the anti-tumor 
effects of sorafenib, and also provide the strong rationale 
for further development of Pin1 inhibitors as a novel 
approach to enhance the therapeutic efficacy of sorafenib 
against HCC, one of the most lethal cancers.
MATERIALS AND METHODS
Cell culture and reagents
HCC cell lines HepG2, Huh7, Hep3B and PLC/
PRF/5 cells were obtained from Cell Bank of Chinese 
Academy of Sciences. HepG2 and Huh7 cells were 
cultured in high glucose DMEM (#12800017; GIBCO), 
while Hep3B and PLC/PRF/5 cells were cultured in 
MEM (#SH30024.01; Hyclone). All medium were 
supplemented with 10% fetal bovine serum (#10437-
028; GIBCO) and 100mg/mL streptomycin and 100U/mL 
penicillin (#SV30010; Hyclone). Cells were incubated 
in 37 degree with 5% CO2. Sorafenib were purchased 
from Santa Cruz Biotechnology (#sc-220125, Santa 
Cruz, CA) and Medchemexpress (#HY-10201, Shanghai, 
China). Antibodies were obtained from the following 
sources. Pin1 antibodies were previously described 
[63]. GAPDH (#HC301-02), beta-actin (#HC201-02), 
beta-tubulin (#HC101-02) were from Transgen (Beijing, 
China). Fbwx7(#55290-1-AP), Mcl-1 (#16225-1-AP) 
and survivin (#10508-1-AP) antibodies were purchased 
from Proteintech (Wuhan, China). Bax (#5023S), 
Phospho-Rb(Ser807/811) (#D20B12) and phospho-
AMPKa(Thr172) (#2535P) antibodies were from Cell 
Signaling Technology (Danvers, MA). Caspase 3 (#PA5-
23921) and Cleaved caspase 9 (#PA5-17913) antibodies 
were from ThermoFisher Scientific (Rockford, IL). ATRA 
(#R2625), MG132 (#C2211), propidium iodide (#P4170) 
and Hoechst33342 (B2261) were obtained from Sigma 
(St. Louis, MO). Cell counting Kt-8 (CCK-8) was from 
were from Transgen (Beijing, China). CellTiter-Glo® 
Luminescent Cell Via- bility Assay Kit was from Promega 
(2800 Woods Hollow Road, Madison, WI, USA). ATRA 
slow releasing pellet (#V-111) was purchased from 
Innovative Research of America (Sarasota, FL).
RNA interference
Pin1 shRNA (5′-CCACCGTCACACAGTATTTAT-3′) 
was previously described [34]. To establish stable Pin1 
knockdown cell lines, Huh7 and HepG2 cells were 
infected with lentiviruses expressing Pin1 shRNA. Stably 
knockdown cells were selected with 0.5 mg/mL puromycin. 
Cell death assay
pI/Hoechst double staining followed by microscopy 
was performed as previously described [35, 36]. Briefly, 
HCC cells were treated as indicated and stained with 
5 ug/mL pI and 5ug/mL Hoechst 33342, examined under 
fluorescence microscopy (Zeiss Axio Observer A1). 
pI positive cells were considered dead or late apoptotic 
cells, whereas Hoechst 33342 positive cells were blue 
and considered normal or early apoptotic cells. pI or 
Hoechst33342 positive cells were counted using Image 
pro plus 6.0 (Media Cybernetics, MD, USA), respectively. 
pI staining followed by flow cytometry was 
conducted as previously described [44]. Briefly, HCC 
cells were treated as indicated and stained with pI 
alone. pI incorporation and cell size were quantified by 
flow cytometry. pI negative cells with normal size were 
considered as live cells. pI positive cells with smaller size 
were considered as dead cells.  
ATP assay
Equal volume of reagents from CellTiter-Glo 
Luminescent Cell Viability Assay Kit was directly added to 
media. Record luminescence at Microplate Luminometer 
(Orion-L2) from BERTHORD, Germany. 
CCK8 assay
10 µL of CCK8 was added into 90 ml of media. Cells 
were then incubated at 37°C and 5% CO2 for one hour. 
Measure the absorbance using Multiscan GO from Thermo 
Scientific at 460 nm. The reference wavelength was 600 nm.
Animal models
All animal protocols were approved by Experimental 
Animal Ethics Committee of Fujian Medical University. 
BALB/c nude mice were maintained in specific-pathogen-
free Laboratory Animal Center of Fujian Medical 
University.
For tumor implantation, 2.5*106 Huh7 cells were 
inoculated subcutaneously onto the left and right flank 
region of ~6 week old nude mice. Tumor volume was 
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measured every three days and calculated by the formula: 
Length*width*width/2. 
For ATRA treatment, one-fourth pellet of 10 mg 
ATRA with slowing releasing formula for 21 days was 
embedded under the neck skin. For sorafenib treatment, 
40 mg/kg sorafenib was given every three days by oral 
gavage.
Statistical analysis
Experiments were routinely repeated at least three 
times. All data are presented as the means ± SD, followed 
by determining significant differences using the two tailed 
student t test.
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